Methadone is now increasingly being used to control opioid withdrawal symptoms, and recently, chronic pain. With increasing reports of cardiac problems induced by methadone, we aimed to determine effect of methadone on hERG expression after chronic treatment with racemic and the two enantiomers (S-and R-) of methadone. The molecular mechanism underlying methadone-disrupted hERG expression in human primary cardiomyocytes was also investigated.
Background
Methadone was first introduced by the United States Public Health Service Hospital in the 1960s as a treatment for opioid abstinence syndrome, and still remains the most widely prescribed and most efficacious treatment for this condition [1] . More recently, methadone is used in palliative care to control chronic cancer pain [2] . Due to its low production cost, fast-acting and long-lasting effect, methadone usage is steadily increasing [3] . The drug is currently administered as a racemic form, composed of a mixture of (R)-and (S)-enantiomers, although (R)-methadone is reported to be primarily responsible for its therapeutic benefit, as racemic-methadone produces a similar therapeutic outcome [4] . (S)-methadone is primarily responsible for off-target, adverse effects [5] .
The human ether-a-go-go-related gene (hERG) encodes a potassium channel that has a critical role in normal heart function. Recent advances have shown that compared with other K + channels, hERG-encoded channels are more susceptible, and extraordinarily sensitive to, drug blockade [6] . Blocking hERG channels causes the drug-induced form of long QT syndrome (LQTS), a cardiac disorder that carries an increased risk of cardiac arrhythmias and sudden death. Therefore, hERG has generated considerable interest in pharmacologically linked arrhythmias.
There has been a significant increase in cases of QT interval prolongation and torsade des pointes (TdP) associated with a wide range of methadone dosages, including those recommended for methadone maintenance treatment and palliative care [79]. With growing concern that chronic methadone treatment can lead to future health problems and major complications, the effect of methadone on hERG needs to be determined.
Many in vitro studies have found that methadone inhibits hERG channels with IC 50 values ranging between 1.7 and 20 µM [1015]. Further in vitro studies have shown methadone-induced QT interval prolongation in isolated perfused rabbit heart [16] and action potentials from human stem-cell derived cardiomyocytes [14] .
Many previous in vitro studies examining drug effects on hERG have used the patch-clamp method to determine acute effects in a hERG-expressing heterologous system e.g., HEK293-hERG [12, 15] . However, for some drugs, hERG blockade may not be detected at the acute treatment stage, but may still affect hERG expression at clinically relevant concentrations. Example of these include arsenic trioxide (anti-cancer), pentamidine (antiinfective/microbial), probucol (cholesterol-lowering drug), and digitoxin (cardiac glycoside), which have all been retracted from the market due to their effect on reducing hERG expression [1720]. Others such as ketoconazole (anti-fungal) and fluoxetine (anti-depressant) acutely block hERG currents and simultaneously disrupt its expression [21, 22] . Notably, growing evidence highlights that defective hERG expression also leads to QT interval prolongation with increased predisposition to cardiac arrhythmias, TdP, and sudden cardiac arrest [23, 24] .
All of these observations on drug-induced alterations in hERG expression are similar to biogenesis defects implicated in the vast majority of examples of hERG mutation-mediated QT prolongation [25] . Serum and glucocorticoid inducible kinase-3 (SGK3) and the 90-kDa heat shock protein (Hsp90) regulate cardiac hERG expression and may be involved in hERG biogenesis defects [26, 27] . Previously, SGK3 and hERG coexpression in Xenopus oocytes was shown to enhance steady-state currents and cell membrane protein abundance [27] . Hsp90 is an abundant molecular chaperone intimately involved in protein folding, activation, and stabilization [28] . Hsp90 inhibitors e.g., geldanamycin, disrupt the Hsp90-ATPase cycle and suppress hERG protein maturation, facilitating its degradation via the ubiquitin-proteasome system [29] .
In this study, we investigated the effect of chronic treatment of racemic-and the two (S-and R-) methadone enantiomers on hERG gene and protein expression in a native cardiomyocyte model system. We also examined SGK3 and Hsp90 mechanisms in methadone disruption of hERG expression. Grand Island, New York, USA). All cultured cells were maintained in a humidified incubator at 37C, 100% relative humidity, and with 5% regulated CO 2 .
Methods

Cell culture
Pharmacology
Three types of methadone were used throughout the study: racemic-, (R)-and (S)-methadone (Toronto Research Chemicals, Toronto, Ontario, Canada). For each type, a single concentration was used, based on published patchclamp data [12] , and corresponding to the IC 50 (i.e., concentration that blocks 50% of hERG currents): 3, 2, and 7 µM, respectively. Stock concentrations (1 mM) were prepared in distilled water and stored at −20C until needed. bp; troponin I, 5-CCAACTACCGCGCTTATGC-3 (F) and 5-CTCGCTCCAGCTCTTGCTTT-3 (R), amplicon size 120 bp; β-actin, 5-ATTGCCGACAGGATGCAGAAG-3 (F) and 5-TAGAAGCATTTGCGGTGGACG-3 (R), amplicon size 203 bp; SGK3, 5-TGTGGGACACCAGAGTATCTTG-3 (F) and 5-AAGGAGGCAATCCATACAGCA-3 (R), amplicon size 118 bp; Hsp90, 5-GACCAGAAATCCCGACGAT-3
Quantitative and semi-quantitative real-time PCR
(F) and 5-AAATGCTTCACTGCCAAGTG-3 (R), amplicon size 96 bp. hERG mRNA expression in treated and untreated control samples was normalized to expression of the housekeeping gene, β-actin. Relative hERG expression using β-actin as the reference gene was calculated based on the threshold cycle number (C T ) of each PCR, according to the Pfaffl method [30] . hERG mRNA expression levels were expressed as fold-difference of levels in treated versus control samples normalized by β-actin.
Western blotting
Total protein was extracted in RIPA buffer, according to the manufacturer's protocol (Thermo Scientific, Grand
Island, New York, USA). Total protein concentration was determined using a standard curve prepared with known concentrations of bovine serum albumin (Sigma-Aldrich). Samples were then prepared for loading onto gels or stored at −20C. For hERG protein detection, total protein extracts were separated on SDS polyacrylamide gels and electrophoretically transferred onto nitrocellulose membranes (Biorad, USA). Bands were detected by chemiluminescence (Nacalai Tesque, Kyoto, Japan). 
Data analysis
Data are presented as mean ± standard error of the mean (SEM) with n = 3. Statistical significance was determined using Student's t-tests. Cardiomyocytes were treated with racemic-, (S)-and (R)-methadone for 5 days, and then total RNA extracted and cDNA synthesized. Relative hERG gene expression was determined by real-time PCR based on the Pfaffl method [30] . Data was collected from n = 3 independent experiments (*P < 0.05). X indicates no significant differences.
Results
Reduced hERG mRNA expression after chronic treatment with racemic-and (S)-methadone
Reduced hERG total protein expression after chronic treatment with racemic and (S)methadone
Western blotting was performed to investigate the effect of IC 50 racemic-, (R)-and (S)-methadone on hERG protein expression in human primary cardiomyocytes. We observed significantly decreased hERG protein expression after 5 days of treatment with (S)-methadone (P < 0.05), but not racemic-or (R)-methadone ( Figure 2 ). 
Modulation of the transcription factor SGK3, but not Hsp90, by racemic-and (S)-methadone
Because racemic-and (S)-methadone significantly affect hERG gene and/or protein expression, the molecular mechanism for this disruption was further investigated by examining expression of the transcription factor, SGK3, and a chaperone protein, Hsp90. SGK3 gene expression was significantly reduced by IC 50 racemic-and S-methadone (P < 0.05) ( Figure 3A) , with no significant effect of R-methadone observed. However, Hsp90 gene expression was not affected by chronic treatment with racemic-, (R)-, and (S)-methadone ( Figure 3B ). according to the Pfaffl method [30] . Data are representative of n = 3 independent repeats with X indicates no significant differences (P > 0.05).
Discussion
Although methadone has been established as a safe drug, reports of methadone-associated arrhythmia have increased substantially from 19972011, with the number of cases of QT interval prolongation and TdP similar to that of other highly proarrhythmic drugs, such as dofetilide [31] . Consequently, there is an urgent need to reassess the effect of methadone on cardiac health.
New evidence is emerging that altered plasma membrane expression of hERG leads to QT interval prolongation with increased predisposition to cardiac arrhythmia and sudden cardiac arrest [23, 24] . Chronic treatment with certain clinically approved drugs, e.g., arsenic trioxide (anti-cancer), pentamidine (anti-infective/microbial), probucol (cholesterol-lowering drug), digitoxin (cardiac glycoside), ketoconazole (anti-fungal), and fluoxetine (antidepressant), disrupts hERG expression and can potentially lead to LQTS [1722]. In the worst cases, these findings have resulted in drug withdrawal from the market.
Here, at a concentration that has been reported to block 50% of hERG channels (IC 50 ), hERG mRNA expression in human cardiomyocytes was significantly reduced after 5 days treatment with racemic-and (S)-methadone, but not (R)-methadone ( Figure 1 ). Thus, it appears that the disruptive effect of (S)-methadone on hERG gene expression is dominantly in the racemic-form.
Altered hERG gene expression by IC 50 (S)-methadone is corroborated by our protein analysis, with hERG protein expression also significantly reduced by (S)-methadone and not (R)-methadone ( Figure 2 ). These results are in accordance with two independent studies showing that (S)-methadone is more potent against hERG-encoded channels than (R)-methadone [11, 12] . However, we did not observe the disruptive effect of (S)-methadone on hERG protein expression in the racemic-form (Figure 2 ), supporting the observations that racemic-methadone produces a similar therapeutic outcome compared with (R)-methadone alone [4] . Nevertheless, replacing racemicwith (R)-methadone in patients receiving maintenance treatment has been shown to reduce QT interval prolongation [5] .
Essentially, the variation/ratios of (R)-and (S)-methadone in the racemic-form may be influencing the therapeutic response [33] . However, there is still inadequate data to show this unequivocally. Furthermore, the magnitude of the effect also depends on an individual's predisposition in drug clearance and interactions [34] .
To further understand the molecular mechanisms of racemic-and (S)-methadone, we examined the involvement of SGK3 and Hsp90. These molecules are implicated in hERG gene transcriptional regulation and protein trafficking to the cardiac plasma membrane, respectively [26, 17] . Altered expression of both molecules in the mechanism of drug-induced hERG expression defects has been reported elsewhere [24] . We found significantly reduced SGK3 gene expression after 5 days treatment with racemic-and (S)-methadone, corroborating studies demonstrating transcriptional regulation of SGK3 on hERG [26, 27] .
hERG abundance in the plasma membrane is a key determinant of hERG functionality. Maturation and trafficking of hERG protein to the plasma membrane is dependent upon chaperone proteins, such as Hsp90 [17, 26] . With the exception of arsenic oxide, the mechanism responsible for reduced trafficking remains unknown, therefore we wanted to examine a potential trafficking mechanism for methadone. We found no significant changes in Hsp90 gene expression with racemic-methadone or either of its isomers. This implies that reduced hERG protein expression following chronic methadone treatment is not regulated by Hsp90. However, in order to ascertain that Hsp90 does not play a role in methadone-reduced hERG expression, further studies must be performed to examine Hsp90 protein levels.
Conclusions
Our findings conclude that chronic racemic-and (S)-methadone, but not (R)-methadone treatment reduces hERG gene expression in human cardiomyocytes, and this involves interruption of transcription factor SGK3 gene expression. Although hERG protein was also affected by chronic (S)-methadone treatment, Hsp90 which plays role in protein maturation and trafficking is not affected by any methadone forms. More work is needed to understand these methadone-induced alterations in hERG expression, and develop further strategies for determining cardiac risk for this drug in which a consideration to prescribe only the (R)-methadone for any treatment is highly recommended.
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